Panel gives new Seroquel use a limited nod

Wednesday was a good news-bad news sort of day for AstraZeneca's Seroquel XR. The extended-release antipsychotic did get an FDA advisory panel's nod for a new use--against depression--but it was far from an unqualified yes. The panelists unanimously agreed that Seroquel shouldn't be a first-line treatment for depression, because it's not safe enough for such widespread use. It could be useful, however, as a supplemental drug for some patients, they said, in a 6-to-3 vote.

AstraZeneca was pitching the committee on a proposed expansion of Seroquel use not only to patients with major depression, but to those with generalized anxiety disorder as well. Panelists determined that Seroquel wasn't significantly more effective than established depression meds as a first-line, standalone treatment. Plus, the drug's well known potential to cause weight gain, high blood sugar and other serious side effects caused concern. "I would expect unintended consequences associated with wide-scale use of the drug," said the panel's chair, Dr. Wayne Goodman of NIMH.

Now that its experts have weighed in, it's up to FDA to make a choice. The agency isn't required to follow the panel's advice, but it usually does.

Despite the endorsement's limits, it could still boost Seroquel sales, observers said. "It's certainly going to help their bottom line, but it's not the great victory they had hoped for," Daniel Carlat, a Tufts University psychiatrist who was not on the advisory panel, told the Philadelphia Inquirer. Carlat said companies can use even narrow approvals to market a drug more widely.

- read the Delaware News-Journal's story
- see the article in the Inquirer

Suggested Articles

The cleaning procedures are so poor at a Zydus Cadila plant in India that the FDA says a sampling found 10 different cross-contaminated products.

Oklahoma politicians contend J&J should be on the line for future abatement costs even after a $572 million verdict, but J&J sees things differently.

Abbott helmsman Miles White, who oversaw the spinoffs of AbbVie and Hospira, will step down as CEO after 21 years at the top job.